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RatFluidity is an important neuronal membrane property and it is inﬂuenced by the concentration of
polyunsaturated fatty acids (PUFAs) in membrane phospholipids. Phospholipase A2 (PLA2) is a key enzyme in
membrane phospholipid metabolism, generating free PUFAs. In Alzheimer disease (AD), reduced PLA2
activity, speciﬁcally of calcium-dependent cytosolic PLA2 (cPLA2) and calcium-independent intracellular PLA2
(iPLA2), and phospholipid metabolism was reported in the frontal cortex and hippocampus. This study
investigated the effects of in vivo infusion of the dual cPLA2 and iPLA2 inhibitor MAFP into rat brain on PLA2
activity and membrane ﬂuidity parameters in the postmortem frontal cortex and dorsal hippocampus. PLA2
activity was measured by radioenzymatic assay and membrane ﬂuidity was determined by ﬂuorescence
anisotropy technique using three different probes: DPH, TMA-DPH, and pyrene. MAFP signiﬁcantly inhibited
PLA2 activity, reduced the ﬂexibility of fatty acyl chains (indicated by increased DPH anisotropy), increased
the ﬂuidity in the lipid–water interface (indicated by decreased TMA-DPH anisotropy), and increased the lipid
lateral diffusion in the hydrocarbon core (represented by pyrene excimer formation) of membranes in both
brain areas. The ﬁndings suggest that reduced cPLA2 and iPLA2 activities in AD brain might contribute to the
cognitive impairment, in part, through alterations in membrane ﬂuidity parameters.phenyl-1,3,5-hexatriene; i.c.v.,
rophosphonate; NMR, nuclear
ylketone; PAF, platelet activat-
atidylcholine; PLA2, phospho-
urated fatty acid; TMA-DPH, 1-
.
: +55 11 3069 7535.
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Neuronal membranes are composed of three main categories of
lipids: glycerophospholipids, phosphosphingolipids, and cholesterol.
Glycerophospholipids constitute the backbone of cell membranes. They
contain a glycerol molecule esteriﬁed with a fatty acid at carbon-1
(usually saturated, such as palmitic acid) and carbon-2 (usually
unsaturated, such as arachidonic acid), and with a phosphoric acid
and a nitrogenous base (choline, ethanolamine, serine or inositol) at
carbon-3. Glycerophospholipids are divided into four major classes: (a)
phosphatidic acid, (b) 1,2-diacyl-glycerophospholipids [phosphatidyl-
choline (PtdCho), phosphatidylethanolamine, phosphatidylserine,
phosphatidylinositol], (c) 1-alch-1-enyl-2-acyl-glycerophospholipids
or plasmalogens, and (d) 1-alkyl-2-acyl-glycerophospholipids [includ-
ing 1-alkyl-2-acyl-glycerophosphocholine, precursor of platelet acti-vating factor (PAF)]. These glycerophospholipids inﬂuence
physicochemical properties of neuronal membranes such as stability,
ﬂuidity, and permeability (Farooqui et al., 2000).
Fluidity is probably themost important physicochemical property of
a cell membrane and is an essential requirement for the optimal
functioning of receptors, membrane-bound enzymes, and ion-channels
(Yehuda et al., 2002). The ﬂuidity of neuronal membranes has been
related to the concentration of polyunsaturated fatty acids (PUFA; such
as arachidonic acid) esteriﬁed to glycerophospholipids. For instance,
Viani et al. (1991) studied the effect of age on the integrity of brain
synaptosomes from young, adult, and old rats, and demonstrated an
age-related increase in synaptosomal free (nonesteriﬁed) PUFAs and a
corresponding age-dependent decrease in membrane ﬂuidity. In
addition, Fukaya et al. (2007) demonstrated that neuronal membrane
ﬂuidity in hippocampal slices from young rats was higher than in
senescent animals, and that long-term dietary supplementation of
senescent rats with arachidonic acid increased neuronal membrane
ﬂuidity, which was comparable to that of young controls. Moreover,
Yang et al. (2010) reported that treatment of primary cultures of rat
cortical neurons with arachidonic acid increased the ﬂuidity of
neuronal membranes when compared with control.
Phospholipases A2 (PLA2) are a diverse family of hydrolytic enzymes
that catalyse the cleavage of fatty acids from the sn-2 position of
membrane glycerophospholipids to generate lysophospholipids and
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extracellular and intracellular enzymes, which are classiﬁed into ﬁve
main groups: (a) calcium-dependent extracellular or secreted PLA2
(sPLA2), (b) calcium-dependent cytosolic PLA2 (cPLA2), (c) calcium-
independent intracellular PLA2 (iPLA2), (d) plasmalogen-selective PLA2,
and (e) PAF-acetylhydrolases (Burke and Dennis, 2009; Ohto et al.,
2005). PLA2 cleaves preferentially membrane PtdCho over other
glycerophospholipids (Larsson et al., 1998; Larsson Forsell et al.,
1999; Nalefski et al., 1998; Nalefski and Falke, 1996; Yang et al.,
1999). PLA2-catalyzed hydrolysis of PtdCho forms lyso-PtdCho and a
free fatty acid including arachidonic acid (Farooqui et al., 1997).
Speciﬁcally, the cPLA2 shows a marked selectivity for arachidonic acid
at the sn-2 position of PtdCho (Song et al., 1999; Underwood et al.,
1998). The iPLA2 shows a preference, although slight, for arachidonic
acid over other fatty acids at the sn-2 position of PtdCho (Mancuso et al.,
2000). The sPLA2 is characterized by a broad speciﬁcity for phospho-
lipids with different polar head groups and fatty acid chains at the sn-2
position, but they are also able to liberate arachidonic acid from PtdCho
(Bezzine et al., 2002; Murakami et al., 2001).
During the last 15 years, we have been interested in the involve-
ment of PLA2 in Alzheimer disease (AD). In 1995, we reported for the
ﬁrst time reduced activity of total PLA2 in the postmortem parietal and
frontal cortices of drug-free subjects with AD (Gattaz et al., 1995). Later,
reduced activity of both cPLA2 and iPLA2 was reported in the
postmortem parietal and temporal cortices of AD subjects, as well as
decreased cPLA2 activity in the hippocampus (Ross et al., 1998).
Decreased iPLA2 activity was also found in the postmortem prefrontal
cortex of frontal AD cases (Talbot et al., 2000). These data are in line
with numerous in vivo nuclear magnetic resonance (NMR) spectros-
copy ﬁndings of decreased membrane phospholipid metabolism in
the brain (prefrontal and parietotemporal cortices and hippocampus)
of patients with mild and moderate AD (Brown et al., 1989; Chantal
et al., 2002; Cuenod et al., 1995; Forlenza et al., 2005; Jessen et al.,
2000; Pettegrew et al., 1988, 1994, 1995). Patients in some of these
studies were reported to be drug-free (Chantal et al., 2002; Forlenza
et al., 2005; Pettegrew et al., 1995). The patients' drug status was not
reported in the other studies on PLA2 activity and membrane metab-
olism in AD brain.
Because PLA2 is a key enzyme in membrane phospholipid metab-
olism, and there are reports of reduced PLA2 activity (speciﬁcally of
cPLA2 and iPLA2 groups) and phospholipid metabolism in the brain of
AD subjects, we performed the present study to investigate the effects
of in vivo infusion of a dual inhibitor of both cPLA2 and iPLA2 groups
into rat brain on the ﬂuidity of membranes isolated from the post-
mortem frontal cortex and dorsal hippocampus.
2. Methods
2.1. Animals
Thirty-six male Wistar rats weighing 270–330 g at the beginning
of the experiments were used in this study. They were obtained from
the Animal Facility of theMedical School of the University of São Paulo
(FMUSP) and kept in conventional facility under constant tempera-
ture (22±1 °C) and humidity (50–60%), on a 12 h light/dark cycle
and ad libitum access to food and water. Animal use procedures were
carried out in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC) tominimize the number
of animals used and their suffering. The study was approved by the
Ethical Committee for the Analysis of Research Projects (CAPPesq
0894/08) of the Clinical Hospital of FMUSP.
2.2. Surgery and drug infusion procedures
Mini-osmotic pumpsdelivering a constant volumeoutput of 1.0 μL/h
(model 1003D, 3 days; Alzet, CA) were ﬁlled either with vehicle alone[3% DMSO in 0.9% NaCl (18 rats: controls)] or vehicle containing 3 mM
methyl arachidonylﬂuorophosphonate [MAFP (18 rats); Biomol, PA] – a
dual inhibitor of both cPLA2 and iPLA2 groups (Balsinde and Dennis,
1996; Lio et al., 1996) – and placed in 0.9% NaCl solution overnight at
37 °C toprime the pumpbefore implantation. Ratswere anesthetized by
intraperitoneal injection of a combination of Ketamine (100 mg/kg) and
Xylazine (10 mg/kg). Supplementary doses of anesthetic were admin-
istered if a limb withdrawal reﬂex was elicited in response to pinching
off a hind footpad. Under anesthesia, thehair on thedorsal surface of the
head was clipped and the animal placed in a stereotaxic apparatus
(David Kopf, CA). A midline incision was made from the level of the
orbits to the occipital crest and the skin and periosteum retracted to
expose the surface of the skull. A small hole was made in the parietal
bone by using a dental drill (Micromotor™ Drill, Stoelting, IL) to allow
implantation of a guide cannula with its tip in the right lateral ventricle,
according to the coordinates of the Atlas of Paxinos andWatson (1998):
1.3 mm posterior to bregma, 1.8 mm lateral to midline, and 3.5 mm
ventral to duramatter. The guide cannulawas securedwith dental glass
ionomer cement and a stainless steel screw that was placed in the
calvariumwith the tip just penetrating thebone. The osmotic pumpwas
implanted by dissecting a subcutaneous pocket under the skin on the
back of the animal, and connected to the intracerebroventricular (i.c.v.)
guide cannula by a 7.5 cm long ﬂexible polyvinylchloride tube (Alzet).
The cannula and tube were covered with dental acrylic cement. During
theperiod of drug delivery (3 days), thewelfare of the animalswasdaily
monitored by recording bodyweight and observing general appearance
(posture, fur) and behaviour (activity, vocalisations, isolation). Only
data from animals showing progressive weight gain and good
appearance were included in the study.
2.3. Preparation of brain tissue
The day of pump implantation is deﬁned as Day 0. On Day 3 after
surgery, the rats were killed by decapitation, the brain was rapidly
withdrawn, and the frontal cortex and dorsal hippocampus were
bilaterally dissected according to visual anatomical landmarks of the
Atlas of Paxinos and Watson (1998) and stored at −70 °C. The brain
tissue was grouped in pools of two, totaling nine pools of frontal
cortex and nine of dorsal hippocampus per group of treatment (DMSO
and MAFP), in order to obtain an average weight of 150 mg per pool
necessary for preparation of total homogenates and crude mem-
branes. Each pool was homogenized in 20 volumes of 5 mM Tris–HCl
buffer pH 7.4 (4 °C). From this preparation (total homogenates),
aliquots were separated for determinations of total protein concen-
tration and PLA2 activity and stored at −70 °C. Then, 15 mL of 5 mM
Tris–HCl buffer pH 7.4 (4 °C) were added to the rest of homogenate.
This preparation was centrifuged at 48,000 g for 20 min at 4 °C. The
resulting pellet was resuspended in 15 mL of 5 mMTris–HCl buffer pH
7.4 (4 °C), and centrifuged again at 48,000 g for 20 min at 4 °C. The
ﬁnal pellet (crude membranes) was resuspended in 3 mL of 5 mM
Tris–HCl buffer pH 7.4 (4 °C). From this suspension, aliquots were
separated for determinations of total protein concentration and
membrane ﬂuidity and stored at −20 °C.
2.4. Determination of PLA2 activity
Prior to PLA2 assay, total protein concentration was determined in
each aliquot of total homogenate by the Bio-Rad DC Protein Assay (Bio-
Rad, Hercules, CA) modiﬁed from the Lowry assay (Lowry et al., 1951).
PLA2 activity was determined by a radioenzymatic assay, as previously
described (Schaeffer and Gattaz, 2005). Brieﬂy, L-α-1-palmitoyl-2-
arachidonyl-phosphatidylcholine labelled with
14
C in the arachidonyl
tail at the sn-2 position (P*APC; PerkinElmer, Boston, MA) was used as
enzyme substrate. Prior to enzymatic reaction, a mixture of P*APC and
toluol-ethanol-butylhydroxytoluol antioxidans (1:10, v/v) was evapo-
rated under a stream of nitrogen (0.06 μCi per sample), resuspended in
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Fig. 1. PLA2 activity (pmol/mg protein/min) is given as mean (±standard deviation).
A 3 day i.c.v. infusion of 3 mM MAFP (n=9) in rats signiﬁcantly reduced PLA2 activity
by 16.9% in the frontal cortex and by 17.8% in the dorsal hippocampus when compared
with control (3% DMSO, n=9). ** pb0.01, *** pb0.001.
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and homogenized by ultrasound. Optimal assay conditions were used
for measuring cPLA2 plus iPLA2 activity in rat brain homogenates, as
previously determined by our group. Thus, total homogenates were
diluted in 50 mM Tris–HCl buffer pH 8.5 (4 °C) to a protein
concentration of 1.5 mg/mL. The assay samples (500 μL, 4 °C) contained
100 mM Tris–HCl buffer pH 8.5, 1 μM CaCl2, 300 μg of protein from
diluted homogenates, and 0.06 μCi P*APC. After incubation for 30 min
at 37 °C, the reaction was stopped by adding a mixture of HCl-isopro-
panol (1:12, v/v). The radioactivity of the liberated [
14
C]arachidonic acid
was measured in a liquid scintillation counter (Tri-Carb 2100TR;
Packard, Meriden, CT) and used for estimating PLA2 activity, which is
expressed in pmol/mg protein/min. All determinationswere performed
in triplicate.
2.5. Determination of membrane ﬂuidity
Prior to membrane ﬂuidity assay, total protein concentration was
determined in each aliquot of membrane suspension by the Bio-Rad
DC Protein Assay. Because biological membranes represent very
heterogeneous media, the knowledge of the ﬂuidity of membrane
compartments requires the use of different probes. In this study,
membrane ﬂuidity was determined by ﬂuorescence anisotropy (or
polarisation) technique using three different ﬂuorescent probes: 1,6-
diphenyl-1,3,5-hexatriene (DPH; Sigma-Aldrich, St. Louis, MO), 1-[4-
(trimethylamino)phenyl]-6-phenyl-1,3,5-hexatriene (TMA-DPH;
Molecular Probes, Eugene, OR), and pyrene (Sigma-Aldrich). DPH is
used for determining the ﬂexibility of fatty acyl chains in the mem-
brane hydrophobic core, and TMA-DPH is used for determining the
ﬂuidity in the region of lipid–water interface (hydrophilic region).
DPH and TMA-DPH anisotropy is inversely correlated with membrane
ﬂuidity (Lentz, 1993). Pyrene is used for determining the lateral
diffusion of total lipids in the membrane hydrocarbon core (bulk
lipid ﬂuidity) as well as the lateral mobility of lipids close to mem-
brane proteins (annular lipid ﬂuidity). The ratio of pyrene excimer to
monomer ﬂuorescence intensities is used for calculating pyrene
excimer formation that correlates with membrane ﬂuidity (Galla and
Hartmann, 1980).
Anisotropy measurements were performed as previously described
(Eckert et al., 2004), with slightmodiﬁcations. Brieﬂy, crudemembrane
suspensions were diluted to a protein concentration of 300 μg/mL with
5 mM Tris–HCl buffer pH 7.4 (4 °C). For the DPH and TMA-DPH assays,
the samples (2 mL) contained 5 mM Tris–HCl buffer pH 7.4, 30 μg of
protein from diluted suspensions, and 33 μMDPH in tetrahydrofuran or
17 μMTMA-DPH in dymethylformamide. After incubation for 45 min at
37 °C, the steady-state anisotropy was measured in a PTI spectroﬂu-
orometer (Photon Technology International, Monmouth Junction, NJ)
using excitation and emission wavelengths of 360 and 450 nm, res-
pectively. For the pyrene assay, the samples (2 mL) contained 5 mM
Tris–HCl buffer pH 7.4 and 100 μg of protein from diluted suspensions.
After incubation for 45 min at 37 °C, 2 μL of 100 mM pyrene in
dymethylformamide were added to samples. After incubation for
2 min, pyrene was excited through energy transfer from intrinsic
tryptophan (excitation wavelength of 286 nm) and ﬂuorescence
emission spectrum was recorded from 360 to 490 nm. After tracing,
pyrene was excited at its own wavelenght (334 nm) and the emission
proﬁle was recorded from 360 to 490 nm. The excimer (at 470 nm) to
monomer (at 373 nm) ﬂuorescence ratio when pyrene was directly
excited and when it was excited via energy transfer from tryptophan
were used for calculating bulk and annular lipid ﬂuidity, respectively.
All determinations were done in triplicate.
2.6. Statistical analysis
Data fromPLA2 activity andmembrane ﬂuidity determinationswere
analyzed by Student's t-test and are expressed as mean (±standarddeviation). Pearson correlation coefﬁcient was calculated to determine
the degree of association between PLA2 activity and membrane ﬂuidity
of individual animals within the MAFP group. Two-tailed proba-
bilitiesb0.05 were considered signiﬁcant.
3. Results
3.1. PLA2 activity
As indicated bymeasurement of the liberated [
14
C]arachidonic acid
from the P*APC substrate, PLA2 activity was signiﬁcantly reduced by
16.9% in total homogenates of the frontal cortex (n=9, t=3.40,
df=16, pb0.01) and by 17.8% in homogenates of the dorsal hip-
pocampus (n=9, t=4.30, df=16, pb0.001) of rats that received i.c.v.
infusion of 3 mM MAFP for 3 days when compared with control rats,
which received i.c.v. infusion of 3% DMSO in saline for 3 days (Fig. 1).
3.2. Membrane ﬂuidity
3.2.1. Anisotropy with DPH
Anisotropy measured with the ﬂuorescent probe DPH was
signiﬁcantly increased in crude membrane preparations of the frontal
cortex (n=9, t=−2.21, df=16, pb0.05) and dorsal hippocampus
(n=9, t=−2.16, df=16, pb0.05) of rats that received 3 day MAFP
when compared with control rats (Fig. 2). No correlation was
observed between reduced PLA2 activity and increased DPH anisot-
ropy in the frontal cortex (r=−0.515, pN0.1) and dorsal hippocam-
pus (r=−0.384, pN0.1) of rats infused with MAFP (data not shown).
3.2.2. Anisotropy with TMA-DPH
Anisotropy measured with the ﬂuorescent probe TMA-DPH was
signiﬁcantly decreased in membrane suspensions of the frontal cortex
(n=9, t=2.34, df=16, pb0.05) and dorsal hippocampus (n=9,
t=2.26, df=16, pb0.05) of rats that received 3 day MAFP when
compared with control rats (Fig. 3). No correlation was observed
between reduced PLA2 activity and decreased TMA-DPH anisotropy in
the frontal cortex (r=0.197, pN0.5) and dorsal hippocampus
(r=0.209, pN0.5) of rats infused with MAFP (data not shown).
3.2.3. Bulk ﬂuidity with pyrene
Bulk ﬂuidity measured with the ﬂuorescent probe pyrene, when it
was directly excited, was signiﬁcantly increased in membrane
preparations of the frontal cortex (n=9, t=−2.29, df=16, pb0.05)
and dorsal hippocampus (n=9, t=−2.40, df=16, pb0.05) of rats
treated with 3 day MAFP when compared with control rats (Fig. 4). No
correlation was observed between reduced PLA2 activity and increased
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Fig. 2. DPH anisotropy is given as mean (±standard deviation). A 3 day i.c.v. infusion of
3 mM MAFP (n=9) in rats signiﬁcantly decreased the ﬂexibility of fatty acyl chains in
the hydrophobic core (indicated by increased DPH anisotropy) from both frontal cortex
and dorsal hippocampus when compared with control (3% DMSO, n=9). * pb0.05.
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Fig. 4. The ratio of pyrene excimer to monomer ﬂuorescence intensities when pyrene
was directly excited (bulk ﬂuorescence) is given as mean (±standard deviation).
A 3 day i.c.v. infusion of 3 mM MAFP (n=9) in rats signiﬁcantly increased the lateral
diffusion of total lipids in the hydrocarbon core (bulk lipid ﬂuidity) from both frontal
cortex and dorsal hippocampus when compared with control (3% DMSO, n=9).
* pb0.05.
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hippocampus (r=−0.480, pN0.1) of rats infused with MAFP (data not
shown).
3.2.4. Annular ﬂuidity with pyrene
Annular ﬂuidity measured with the ﬂuorescent probe pyrene,
when it was excited via energy transfer from tryptophan, was not
signiﬁcantly changed in crude membrane suspensions of the frontal
cortex (n=9, t=1.21, df=16, pN0.1) and dorsal hippocampus
(n=9, t=−0.78, df=16, pN0.5) of rats treated with 3 day MAFP
when compared with control rats (Fig. 5).
4. Discussion
In this study, we demonstrated that 3 day infusion of a dual
inhibitor of both cPLA2 and iPLA2 groups, MAFP, into rat brain
signiﬁcantly inhibited the enzyme activity in both frontal cortex and
dorsal hippocampus, and altered different parameters of the ﬂuidity
of brain membranes in opposite ways. Speciﬁcally, inhibition of PLA2
reduced the ﬂexibility of fatty acyl chains in the membrane
hydrophobic core (indicated by increased DPH anisotropy) and
increased the ﬂuidity in the region of lipid–water interface (hydro-
philic region; indicated by decreased TMA-DPH anisotropy) in both
frontal cortex and dorsal hippocampus. Furthermore, inhibition of
PLA2 increased the lateral diffusion of total lipids in the membrane0,21
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Fig. 3. TMA-DPH anisotropy is given as mean (±standard deviation). A 3 day i.c.v.
infusion of 3 mM MAFP (n=9) in rats signiﬁcantly increased the ﬂuidity in the region
of lipid–water interface (indicated by decreased TMA-DPH anisotropy) from both
frontal cortex and dorsal hippocampus when compared with control (3% DMSO, n=9).
* pb0.05.hydrocarbon core (bulk lipid ﬂuidity; represented by pyrene excimer
formation when pyrene was directly excited), but it did not change
the ﬂuidity of lipids close to membrane proteins (annular lipid
ﬂuidity; represented by pyrene excimer formation when pyrene was
excited via energy transfer from tryptophan) in both frontal cortex
and dorsal hippocampus. No correlation was observed between
reduced PLA2 activity and increased DPH anisotropy, decreased
TMA-DPH anisotropy, or increased pyrene excimer to monomer
ratio, a result that may have been affected by the small sample size.
However, considering the present ﬁndings of reduction of PLA2
activity and alteration of membrane ﬂuidity in the same animals, we
conclude that it is worth investigating the relationship between PLA2
and membrane ﬂuidity in a larger sample.
To our knowledge, this is the ﬁrst study to demonstrate the effects
of PLA2 inhibition on speciﬁc parameters of membrane ﬂuidity. In a
previous study conducted by our group (Schaeffer et al., 2005), we
demonstrated that acute infusion of a dual cPLA2 and iPLA2 inhibitor,
palmitoyl triﬂuoromethylketone (PACOCF3), into the CA1 region of rat
hippocampus prevented the increase of fatty acid chain ﬂexibility in
the membrane hydrophobic core induced by training in a contextual
learning task (inhibitory avoidance). Moreover, the present study is
the ﬁrst to demonstrate distinct changes of ﬂuidity in different1,5
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Fig. 5. The ratio of pyrene excimer to monomer ﬂuorescence intensities when pyrene
was excited through energy transfer from tryptophan (annular ﬂuorescence) is given as
mean (±standard deviation). A 3 day i.c.v. infusion of 3 mM MAFP (n=9) in rats did
not signiﬁcantly changed the lateral diffusion of lipids close to membrane proteins
(annular lipid ﬂuidity) from both frontal cortex and dorsal hippocampus when
compared with control (3% DMSO, n=9).
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related to the concentration of PUFAs and degree of fatty acid
unsaturation (i.e., number of double bonds) in membrane phospho-
lipids, as summarized below.
It is well established that the ﬂuidity of neuronal membranes is
related to the concentration of PUFAs (such as arachidonic acid)
esteriﬁed to glycerophospholipids (Fukaya et al., 2007; Viani et al.,
1991; Yang et al., 2010; Yehuda et al., 2002). However, there are few
studies in the literature relating speciﬁc parameters of brain membrane
ﬂuidity to the concentration of PUFAs. One study, conducted by Fukaya
et al. (2007), examined membrane lateral mobility using the live cell
imaging technique Fluorescent Recovery After Photobleaching and
showed that long-term dietary supplementation of senescent rats with
arachidonic acid increased the lipid lateral diffusion in hippocampal
neuronal membranes, which was comparable to that of young controls.
Another study, carried out by Swapna et al. (2006), demonstrated a
decrease in the amount of monounsaturated fatty acids and PUFAs
(including arachidonic acid) aswell as a decrease in the lateral diffusion
of lipids near proteins (annular lipid ﬂuidity) in membranes isolated
from the cerebral cortex of rats during thioacetamide-induced hepatic
encephalopathy. Through the use of the pulsed-ﬁeld gradient NMR
technique, Filippov et al. (2007) demonstrated that the lipid lateral
diffusion in lipid bilayers made of monosaturated PtdCho increased
with increasing unsaturation in the sn-2 fatty acyl chain (including
arachidonic acid) of PtdCho. In accordance with theoretical predictions,
the authors concluded that the increased lateral diffusion was a
consequence of the increased free headgroup area of the PtdCho caused
by the unsaturation. This is consistent with NMR spectroscopy (Holte
et al., 1996) and computer simulation (Murzyn et al., 2001) studies on
the inﬂuence of the degree of membrane unsaturation on the lipid–
water interface. Such studies in phospholipid bilayers made of PtdCho
containing a saturated fatty acid, a monounsaturated fatty acid, or a
PUFA (including arachidonic acid) in the sn-2 position showed that
increasing degrees of unsaturation increased the surface area available
to (i.e., the distance between) PtdCho headgroups. Finally, the effect of
the degree of membrane unsaturation on the ﬂexibility of fatty acyl
chains was assessed by DPH anisotropy in CHO cells enriched with a
saturated fatty acid, a monounsaturated fatty acid, or a PUFA (including
arachidonic acid; C20:4) (Berlin et al., 1996). The study showed that
cells enriched with unsaturated fatty acids were more ﬂuid than those
enriched with saturated fatty acids, however, PUFAs-enriched cells
were less ﬂuid than monounsaturated fatty acid-enriched cells.
Correlation analyses indicated that the acyl chain ﬂexibility was
inversely related to longer chain PUFAs (≥20 C atoms) with multiple
(≥4) double bonds, suggesting that longer fatty acids such as
arachidonic acid tend to reduce the ﬂexibility of fatty acyl chains in
the hydrophobic core, as constraints are introduced in the conformation
of themembrane phospholipids due to additional kinks in the fatty acyl
tails for each double bond.
The ﬁndings of the present study showing distinct changes of
ﬂuidity in different membrane regions following PLA2 inhibition
appear to be consistent with the studies of the literature reported
above. Once the cPLA2 and iPLA2 groups (which are targeted byMAFP)
cleave mainly arachidonic acid from membrane PtdCho (Mancuso
et al., 2000; Song et al., 1999; Underwood et al., 1998), it is likely that
the inhibition of brain PLA2 in this study may have resulted in
increased concentration of PUFAs (mainly arachidonic acid) esteriﬁed
at the sn-2 position of membrane phospholipids (mainly PtdCho),
thus changing the ﬂuidity of speciﬁc regions of the membrane in
different ways as observed herein (and supported by the literature),
i.e., reducing the ﬂuidity between the fatty acyl tails of a phospholipid
molecule (indicated by increased DPH anisotropy), increasing the
distance between phospholipid headgroups in the lipid–water
interface (hydrophilic region; indicated by decreased TMA-DPH
anisotropy), and increasing the lateral mobility of total lipids in the
central hydrocarbon region of the membrane bilayer (represented bypyrene excimer formation). Still, according to the literature, which
suggested that the increased lateral diffusion of lipids in membrane
bilayers was a result of the increased free headgroup area (hydrophilic
region) of unsaturated membranes (Filippov et al., 2007), in the
present studywe observed changes in the ﬂuidity of these two regions
in the same way, i.e., increased ﬂuidity in both hydrophilic and total
lipid regions of the membrane.
The data of this study showing that inhibition of brain PLA2 (likely
of cPLA2 and iPLA2 groups) lead to alterations in the ﬂuidity of
membranes from the frontal cortex and hippocampus are of interest
in AD in face of previous reports on reduced cPLA2 and iPLA2 activities
(Ross et al., 1998; Talbot et al., 2000) and membrane phospholipid
metabolism (Brown et al., 1989; Chantal et al., 2002; Cuenod et al.,
1995; Forlenza et al., 2005; Jessen et al., 2000; Pettegrew et al., 1988,
1994, 1995) in these brain areas in AD. Postmortem studies of AD
brains demonstrated that reduced PLA2 activity was correlated with
the severity of dementia (Gattaz et al., 1995, 1996), and in vivo NMR
spectroscopy studies of AD brains showed that decreased phospho-
lipidmetabolismwas correlatedwith the severity of cognitive decline,
speciﬁcally in the areas of memory, visual perception, orientation, and
abstract thinking (Forlenza et al., 2005). In face of these data, we
speculate that altered brain membrane ﬂuidity mediated by reduced
PLA2 activity might contribute to the cognitive impairment in AD.
Further studies should clarify whether the MAFP-induced changes in
membrane ﬂuidity in the frontal cortex and hippocampus are also
associated with altered cognitive abilities assessed in frontal cortex-
and/or hippocampus-dependent behavioural tasks, what could open
new avenues for the development of treatment strategies for AD
through stimulation of PLA2.
5. Conclusion
The ﬁndings of the present study suggest that inhibition of brain
PLA2 alters different membrane regions in a complex way. In
summary, this study showed that 3 day infusion of MAFP (dual
cPLA2 and iPLA2 inhibitor) into rat brain signiﬁcantly inhibited PLA2
activity in the frontal cortex and dorsal hippocampus. Additionally,
treatment of rats with MAFP altered different parameters of the
ﬂuidity of brain membranes in opposite ways, i.e., reduced the
ﬂexibility of fatty acyl tails in the hydrophobic core, increased the
ﬂuidity in the region of lipid–water interface (hydrophilic region),
and increased the lateral diffusion of lipids in the hydrocarbon core of
membranes from the frontal cortex and dorsal hippocampus. The
alterations in brain membrane ﬂuidity after PLA2 inhibition observed
in the present study might have implications in AD pathology, since
reduced PLA2 activity (speciﬁcally of cPLA2 and iPLA2 groups) and
membrane phospholipid metabolism were reported in AD brain and
correlated with cognitive impairment.
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